One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1016/s1473-3099(21)00764-7
Copy DOI Journal: The Lancet Infectious Diseases |  Publication Date: Jan 25, 2022 |
 Citations: 55 |  License type: elsevier-specific: oa user license |
Affiliation: Sanofi (United Kingdom), National Institute of Health (NIH), Rockville, MD, USA., Universidad Metropolitana de Honduras, Sanofi (United States), Asociación Colombiana de Facultades de Ingeniería, Honduras Foundation for Agricultural Research, Fred Hutchinson Cancer Center, GlaxoSmithKline (Belgium), TechData Service Company, King of Prussia, PA, USA., National Institute of Allergy and Infectious Diseases, Charles R. Drew University of Medicine and Science, Sanofi (France), George Washington University, Yale University, Synexus (United States)Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
